Serban Ghiorghiu
AstraZeneca (Switzerland)(CH)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer therapeutics and mechanisms, Colorectal Cancer Treatments and Studies, Lung Cancer Research Studies, Tuberculosis Research and Epidemiology
Most-Cited Works
- → Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer(2016)3,266 cited
- → AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer(2014)2,182 cited
- → AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer(2015)2,095 cited
- → Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study(2016)636 cited
- → Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component(2017)565 cited
- → Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer(2017)526 cited
- Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer(2017)
- → Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck(2009)380 cited
- → Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study(2008)217 cited
- → Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small cell lung cancer (NSCLC).(2014)139 cited